Quarterly report pursuant to Section 13 or 15(d)

Related Party Transaction - Additional Information (Detail)

v3.8.0.1
Related Party Transaction - Additional Information (Detail)
3 Months Ended 9 Months Ended 12 Months Ended 16 Months Ended 20 Months Ended
Jul. 24, 2017
USD ($)
$ / shares
shares
Jul. 20, 2017
shares
Jul. 19, 2017
shares
Jul. 18, 2017
USD ($)
$ / shares
shares
Mar. 07, 2017
USD ($)
Sep. 30, 2015
USD ($)
$ / shares
shares
May 18, 2015
USD ($)
Mar. 31, 2018
USD ($)
$ / shares
Sep. 30, 2016
USD ($)
Dec. 31, 2017
USD ($)
$ / shares
Dec. 31, 2016
USD ($)
NotesPayable
Dec. 31, 2016
USD ($)
Dec. 31, 2016
USD ($)
Jul. 31, 2017
USD ($)
Related Party Transaction [Line Items]                            
Common stock, par value | $ / shares               $ 0.001   $ 0.001        
Ricanto, Ltd [Member]                            
Related Party Transaction [Line Items]                            
Consulting fees incurred, related parties                 $ 100,000 $ 0        
Related party consulting agreement, date of termination               Aug. 01, 2017            
Accounts payable, related parties       $ 600,000       $ 0     $ 600,000 $ 600,000 $ 600,000  
Shares issued to related party for services | shares       475                    
Shares issued to related party, par value | $ / shares       $ 0.01                    
Ricanto, Ltd [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock                            
Related Party Transaction [Line Items]                            
Conversion of each outstanding share of Achieve common stock , shares converted | shares       359.3053                    
Number of shares post-conversion | shares       170,670                    
Chief Executive Officer [Member]                            
Related Party Transaction [Line Items]                            
Accounts payable, related parties               0            
Notes payable, related parties                     $ 200,000 200,000 200,000  
Number of notes payable | NotesPayable                     2      
Notes payable, rate of interest                     3.50%      
Notes payable repayment period                     1 year      
Outstanding principal, included in shareholder loans                     $ 200,000 200,000 200,000  
Accrued interest owed to related party               0     3,000 3,000 3,000  
Salary paid                         0  
Chief Executive Officer [Member] | Accrued Compensation [Member]                            
Related Party Transaction [Line Items]                            
Accrued salaries                     700,000 700,000 700,000  
Accrued salaries, common stock shares issued | shares     238                      
Percentage of common stock issued in settlement of accrued salaries     50.00%                      
Percentage of cash payment in settlement of accrued salaries     50.00%                      
Chief Executive Officer [Member] | Accrued Liabilities Other [Member]                            
Related Party Transaction [Line Items]                            
Accounts payable, related parties               300,000            
Chief Executive Officer [Member] | Convertible Notes Payable [Member]                            
Related Party Transaction [Line Items]                            
Shares issued to related party, par value | $ / shares $ 0.01                          
Debt conversion, converted instrument, amount $ 200,000                          
Debt conversion, converted instrument, shares issued | shares 146                          
Chief Executive Officer [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock                            
Related Party Transaction [Line Items]                            
Conversion of each outstanding share of Achieve common stock , shares converted | shares 359.3014   359.3025                      
Number of shares post-conversion | shares 52,458   85,514                      
Lender                            
Related Party Transaction [Line Items]                            
Accounts payable, related parties               0     700,000 700,000 700,000  
Notes payable, related parties         $ 20,000                  
Notes payable, rate of interest         3.50%                  
Notes payable repayment period         1 year                  
Accrued interest owed to related party               0     35,000 35,000 35,000  
Debt conversion, converted instrument, amount $ 800,000                          
Debt conversion, converted instrument, shares issued | shares 586                          
Common stock, par value | $ / shares $ 0.01                          
Lender | Convertible Promissory Note [Member]                            
Related Party Transaction [Line Items]                            
Notes payable, related parties             $ 2,700,000              
Notes payable, rate of interest             3.50%              
Debt conversion, converted instrument, amount           $ 2,000,000                
Debt conversion, converted instrument, shares issued | shares           4,500                
Common stock, par value | $ / shares           $ 0.01                
Lender | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock                            
Related Party Transaction [Line Items]                            
Conversion of each outstanding share of Achieve common stock , shares converted | shares 359.3052                          
Number of shares post-conversion | shares 1,827,426                          
Chief Financial Officer [Member]                            
Related Party Transaction [Line Items]                            
Salary paid                       0    
Chief Financial Officer [Member] | Accrued Compensation [Member]                            
Related Party Transaction [Line Items]                            
Accrued salaries                     $ 300,000 $ 300,000 $ 300,000  
Accrued salaries, common stock shares issued | shares   127                        
Percentage of common stock issued in settlement of accrued salaries   50.00%                        
Percentage of cash payment in settlement of accrued salaries   50.00%                        
Chief Financial Officer [Member] | Accrued Liabilities Other [Member]                            
Related Party Transaction [Line Items]                            
Accounts payable, related parties               200,000            
Chief Financial Officer [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock                            
Related Party Transaction [Line Items]                            
Conversion of each outstanding share of Achieve common stock , shares converted | shares   359.2992                        
Number of shares post-conversion | shares   45,631                        
Michelle Griffin [Member] | OncoGenex Pharmaceuticals, Inc [Member]                            
Related Party Transaction [Line Items]                            
Termination fee payable                           $ 600,000
Michelle Griffin [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Accrued Liabilities Other [Member]                            
Related Party Transaction [Line Items]                            
Accounts payable, related parties               $ 0